Myricx Bio
Myricx Bio formerly Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer. The company received an initial £4.5 million in seed financing from Sofinnova Partners and Brandon Capital Partners.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
myricxpharma.com
Related News
Myricx Bio announces Board Changes
Myricx Bio announces £90m ($114m) Series A financing to advance its novel NMTi-ADC therapeutics into clinical development
Myricx Bio enters into an exclusive antibody license agreement with WuXi Biologics
Myricx Bio appoints Dr Chris Martin, biotech entrepreneur and ADC pioneer, as Chairman of its Board of Directors
Myricx enters into antibody license agreement with Biocytogen
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.